Global Intravenous Immunoglobulin (IVIG) Market: Snapshot

The global market for intravenous immunoglobulin (IVIG) products and therapies is heading in a positive direction due to several innovative techniques and advantages it offers to clinicians worldwide. The market is expected to expand at a healthy pace in the near future. Factors that will support market’s growth include technological improvements in the methods used for production and purification of IVIG products and an improving health care infrastructure across the globe. The rising patient pool suffering from immunological and neurological disorders, mounting geriatric population, and rising production of IVIG products are also expected to have a significant positive impact on market’s future growth prospects.

Transparency Market Research estimates that the market will exhibit a healthy 8.5% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which valued at US$7.23 bn in 2015, is expected to reach US$14.92 bn in 2024. 

intravenous immunoglobulin market

Hospitals to Retain Dominance but Lose Promise to Home Care

In terms of end users of IVIG infusion therapy and products, the global IVIG market is segmented into hospitals, clinics, and home care settings. Of these, the hospitals segment is presently the dominant end user of the intravenous immunoglobulin (IVIG) market. A continuous rise in the number of patients opting for hospitals rather than clinics is the major driver of the hospitals segment. High budgetary expenditure, rising government investment, and better reimbursement policies also augment the number of patients opting hospitals for intravenous immunoglobulin (IVIG) therapies. 

IVIG infusion therapy is a time consuming procedure, in which the infusion takes place at a slow rate and lasts for a long period of time. This factor is also expected to increase consumer preference to home care settings for treatment. Although the hospitals segment will continue to lead the global IVIG market, the rising inclination to home care is expected to make home care the most lucrative end-user segment of the intravenous immunoglobulin (IVIG) market over the forecast. 

Market in North America to Continue to Remain Highly Lucrative

North America is presently the dominant regional market for intravenous immunoglobulin (IVIG) and is likely to witness significant growth during the forecast period as well. In the U.S., North America’s most lucrative IVIG market, the demand for IVIG infusion therapy is driven by the country’s strong economy, advancements in technology, abundant plasma supply, and rising prevalence of immunological disorders. Other factors ascribable to market growth include the favorable reimbursement policies, high investments in research and development, and increasing geriatric population in the country.

FDA’s approval for payments to plasma donors to encourage plasma donation and boost yield is another major factor driving the IVIG market in the U.S. This has helped the country to not only become self-sufficient in plasma supply, but also a major exporter of plasma derived products globally, consecutively strengthening the North America market.

The IVIG market in Europe is also witnessing strong growth owing to increasing patient pool and geriatric population. Higher acceptance of innovative technologies and launch of new products in the region are also driving the IVIG market. Additionally, the ongoing clinical development of new products is anticipated to boost market growth during the forecast period. Asia Pacific is expected to be a promising market for intravenous immunoglobulin (IVIG) due to developing economies and presence of large underserved patient population. The number of patients suffering from immunological diseases is also high in the region, naturally increasing the demand for intravenous immunoglobulin products and therapies.

Some of the key vendors operating in the highly consolidated global IVIG market are Baxalta Incorporated, Biotest AG, CSL Behring LLC, China Biologic Products, Inc., Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, and Sanquin Plasma Products B.V.

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements. 

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Humoral Immunodeficiency
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia
  • Others

Global Intravenous immunoglobulin (IVIG) Market, by End-user

  • Hospitals
  • Clinics
  • Home Care

Global Intravenous immunoglobulin (IVIG) Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa